SecBot SecBot

ZOMDF

Zomedica Corp.
OTC· Pharmaceutical Preparations· Inc. A0· CIK 0001684144 Biotech & Drug Discovery
$0.0850 +0.00 (+3.66%)
Oct 26 4:00 PM ET · prev $0.0820
Next earnings
Nov 3
in 7 days
1 year
+21.4%
from $0.0700 · Oct 27
30 days
+6.3%
from $0.0800
52-week range
$0.0700–0.1540
−45% from high · low Oct 27
Avg volume 20D
754.4K
shares / day
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q4 2024 13F · 0 exits
Filing reports
2
analyzed by SecBot
SecBot read BULLISH 2 reports · latest
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 3, 2026
Strongest BULLISH Zomedica reported record Q1 2026 revenue of $8.8M (+35% YoY), driven by diagnostics growth (+73%) and…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q4 2024: 6 added (0 new), 2 trimmed or exited.

  • TrendUPTREND

    3% above its 50-day average.

Who's buying

13F· Q4 2024
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGDOUBLED3,935,437$472.3K
JANE STREET GROUP, LLCDOUBLED536,856$64.4K
LPL Financial LLCADD383,995$46.1K
WELLS FARGO & COMPANY/MNDOUBLED255,001$30.6K
GABELLI FUNDS LLCDOUBLED225,000$27.0K
JPMORGAN CHASE & CODOUBLED24,410$2.9K
OSAIC HOLDINGS, INC.NEAR_EXIT4,100$492.00
Farther Finance Advisors, LLCNEAR_EXIT650$78.00

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 3, 2026
Earnings date
ZOMDF Q3 2026 Earnings Scheduled — 2026-11-03
Recent
Aug 4, 2026
Earnings date
ZOMDF Q2 2026 Earnings Scheduled — 2026-08-04

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 5, 2026
Blair Anthony K
COO
AWARD500,000 sh
Aug 5, 2026
Klass Russell Kevin
Sr Vice President, Sales
AWARD250,000 sh
Aug 5, 2026
DeHaan-Fullerton Karen
General Counsel
AWARD250,000 sh

Earnings setup

Estimates
Nov 3
reports in 7 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 5, 2026 Insider
Blair Anthony K was granted 500,000 shares
COO
Aug 5, 2026 Insider
Klass Russell Kevin was granted 250,000 shares
Sr Vice President, Sales
Aug 5, 2026 Insider
DeHaan-Fullerton Karen was granted 250,000 shares
General Counsel
Aug 4, 2026 Earnings calendar
ZOMDF Q2 2026 Earnings Scheduled — 2026-08-04
May 6, 2026 SEC
Zomedica reported record Q1 2026 revenue of $8.8M (+35% YoY), driven by diagnostics growth (+73%) and consumables…
8-K — Impact 6/10
Apr 24, 2026 SEC
Zomedica Corp. filed a DEFA14A, which is a definitive proxy statement related to a shareholder vote. The filing…
DEFA14A — Impact 3/10
Dec 31, 2024 Inst.
UBS Group AG — DOUBLED
3,935,437 shares ($472.3K)
Dec 31, 2024 Inst.
JANE STREET GROUP, LLC — DOUBLED
536,856 shares ($64.4K)

SecBot reports

2 filings · 1 bullish · 0 bearish · 1 neutral
All ZOMDF filing & press-release reports (2)